Bone/Obesity/Diabetes/Lipids Flashcards
Atorvastatin
MOA:
HMG-CoA reductase inhibitor
Clinical uses:
hyperlipidemia, coronary artery disease, acute coronary syndrome
Toxicity:
myopathy, hepatic dysfunction
Extra info:
effective at night, long duration of action
Evolocumab
MOA:
PCSK9 inhibitor, increases the number of cell surface LDL receptors
Clinical uses: hyperlipidemia, coronary artery disease, acute coronary syndrome
Toxicity:
myopathy, nausea, cognitive effects
Extra info: monoclonal antibody, 2x month SC injection, price ($$$)
Gemfibrozil
MOA:
PPAR-α agonist
lower TG and raise HDL
Clinical uses:
hypertriglyceridemia, dysbetalipoproteinemia
Toxicity:
myopathy, hepatic dysfunction
Extra info:
combine with statins
Colestipol
MOA:
bile acid binding resin
Clinical uses:
primary hypercholesterolemia, high LDL
Toxicity:
GI effects
Extra info:
combine with statins
Ezetimbe
MOA:
inhibits NPC1L1 cholesterol transporter
Extra info:
primary hypercholesterolemia, high LDL
Toxicity:
GI effects, hepatic dysfunction
Extra info:
combine with statins
Niacin
MOA:
diacylglycerol acyl-transferase 2 inhibitor, GPCR 109A agonist
inhibits production of VLDL and delays HDL clearance
Toxicity:
primary hyperlipidemias, high LDL/VLDL
Toxicity:
flushing, hyperuricemia, pruritus, diabetes, gout
Extra info:
combine with statins, bile acid binding resin
Glipizide
MOA:
K+ channel blocker in pancreatic beta cells, increases insulin secretion
Clinical uses:
Type 2 diabetes
Toxicity:
hypoglycemia, weight gain
Extra info:
oral
Metformin
MOA:
decreases hepatic gluconeogenesis, molecular mechanism not understood
Clinical uses:
Type 2 diabetes, polycystic ovarian syndrome
Toxicity :
GI disturbances
Extra info:
oral
Pioglitazone
MOA:
PPAR- agonist
Clinical uses:
Type 2 diabetes
Toxicity:
fluid retention, anemia, weight gain, myocardial ischemia risk, bone fractures in women
Extra info:
oral, increases transcription of genes involved in carbohydrate and lipid metabolism
Empagliflozosin
MOA:
sodium glucose co-transporter 2 (SGL2) inhibitor
located in the proximal tubule responsible for glucose reasbp.
Clinical uses:
Type 2 diabetes
Toxicity:
osmotic diuresis, UTIs
Extra info:
oral, blocks glucose reabsorption in the kidney proximal tubule
Liraglutide
MOA:
glucagon receptor agonist
Clinical uses:
Type 2 diabetes
Toxicity:
hypoglycemia
Extra info:
stimulates insulin secretion, once daily injectable derivative of human GLP-1, long-acting due to serum albumin binding
Sitagliptin
MOA:
dipeptidyl peptidase-4 inhibitor
Clinical uses:
Type 2 diabetes
Toxicity:
rhinitis, upper respiratory tract infections
Extra info:
oral
Insulin glargine
MOA:
insulin analog
Clinical uses:
type 1 and type 2 diabetes
Toxicity :
hypoglycemia
Extra info:
long-acting (>20 hours), SC injection
Insulin lispro
MOA:
insulin analog
Clinical uses:
type 1 and type 2 diabetes
Toxicity:
hypoglycemia
Extra info:
rapid-acting (minutes), injected SC postprandial
Insulin
MOA:
insulin receptor agonist
Clinical uses:
type 1 and type 2 diabetes
Toxicity:
hypoglycemia
Extra info:
short-acting, multiple delivery systems